Healthcare / Drug Manufacturers - Specialty & GenericBSE
$64.50
-0.96 (-1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-70.5M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
10.4%
↑Gross Margin
98.4%
↑Debt/Equity
-1.38
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-23.1%
FCF CAGR
—
FCF margin
-21.5%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $237.3M · net income $-169.3M · FCF $-50.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $237.3M | $237.3M | $433.1M | $504.2M | $521.3M |
| Net Income | $-169.3M | $-169.3M | $-269.4M | $-197.3M | $-246.9M |
| EBITDA | $-34.2M | $-34.2M | $-143.2M | $-82.8M | $-151.6M |
| EPS | — | — | -12.49 | -9.15 | -11.30 |
| Gross Margin | 98.4% | 98.4% | 87.2% | 38.2% | 18.8% |
| Operating Margin | -50.0% | -50.0% | -50.1% | -30.7% | -42.1% |
| Net Margin | -71.4% | -71.4% | -62.2% | -39.1% | -47.4% |
| Balance Sheet | |||||
| Debt/Equity | -1.38 | -1.38 | -1.45 | -2.00 | -2.30 |
| Current Ratio | 0.09 | 0.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-50.9M | $-50.9M | $-114.5M | $-70.5M | $-355.8M |
| Returns | |||||
| ROE | 10.4% | 10.4% | 18.4% | 16.5% | 24.8% |
| Growth & Yield | |||||
| Revenue Growth | -45.2% | -45.2% | -14.1% | -3.3% | — |
| EPS Growth | — | — | -36.5% | 19.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.49 → n/d
Residual
-12.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.